ナノボディ市場調査レポート：2030年までの予測

Nanobody Market Research Report Forecast till 2030

ナノボディ市場調査レポート：2030年までの予測市場概要ナノボディ市場は、予測期間中に17.88%の健全なCAGRを記録すると推定される。持続性疾患の優位性の高まり、正確な薬物療法への関心の高まり、ナノボ... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Market Research Future マーケットリサーチフューチャー (MRFR)	2023年11月10日	US$7,250 ライセンス・価格情報・注文方法はこちら	128	英語

目次
図表リスト

サマリー

ナノボディ市場調査レポート：2030年までの予測

市場概要
ナノボディ市場は、予測期間中に17.88%の健全なCAGRを記録すると推定される。持続性疾患の優位性の高まり、正確な薬物療法への関心の高まり、ナノボディ革新的研究への関心の拡大が、市場発展の原動力となっています。
ナノボディは、従来の抗体と比較して、より顕著な強度、より優れた組織浸潤性、免疫原性の低下など、いくつかの優位性を享受する小さな逆作用剤部分である。免疫系疾患やその他の進行中の問題の一般性の高まりは、それらの治療のために、より新鮮で実行可能なナノボディをベースとした薬剤の発見を要求している。例えば、2019年2月、米国食品医薬品局（FDA）は、Sanofi S.A.（フランス）の主要なナノボディベースの薬であるCablivi（caplacizumab-yhdp）を、得られた血栓性血小板減少性紫斑病（aTTP）の成人に対して承認した。
世界保健機関（WHO）によると、悪性成長、心血管疾患、糖尿病などの進行中の感染症は、国際的な全死亡の74％を占めている。これらの病気の割合と優勢は、成熟した人口、進化する生活様式、拡大する都市化などの変数によって、上昇し続けると考えられている。その結果、現在進行中の疾病の蔓延の高まりとナノボディの優れた利点が、市場発展の原動力となっている。

市場セグメンテーション
ナノボディ市場は、タイプに基づき、単特異的および多特異的に区分される。
ナノボディ市場は、治療、診断、研究などの用途に基づいて細分化される。治療分野はさらに、がん、神経変性疾患、感染症、その他に区分される。
エンドユーザーに基づくと、市場は研究所、製薬＆バイオテクノロジー企業、その他に区分される。
地域別分析
北米ナノボディ市場は2022年に最大の市場シェアを占めた。同地域の市場成長は、薬物暴露におけるナノボディ革新に関連する大きな心構えと、創製費用を削減するための改良に起因している。Proteintech Gathering, Inc.（米国）やGenscript Biotech Organization（米国）のような組織は、ナノボディのさらなる開発に効果的に取り組んでおり、顧客の要望を満たしている。Genscript Biotech Partnership（米国）は、徹底的な調査と有用なナノボディ応用管理サービスを提供しており、いくつかの試験研究において、同組織は実りある学習経験を与えている。
欧州のナノボディ市場は、ダイナミックな市場プレイヤーの存在、ナノボディ新企業の発展、抵抗できない、神経、病気などの病気の優位性の拡大により、第2位の市場を占めている。
アジア太平洋地域のナノボディ市場は、老年人口の増加、悪性成長および抵抗力のない病気の優位性の拡大、アジア太平洋地域における検査能力のさらなる発展により、最も速い成長を遂げると考えられている。さらに、中国ナノボディ市場は最大の市場提供を保持し、インドナノボディ市場は、アジア太平洋地域で最も急速に発展している通常の市場であると思われる。
主要企業
世界のナノボディ市場における主要企業は、Sanofi（フランス）、Merck KGaA（ドイツ）、BIOCYTOGEN（米国）、Proteintech Group, Inc（米国）、Novartis AG（スイス）、GenScript（米国）、Sensei Biotherapeutics, Inc（米国）、Beroni Group（オーストラリア）、ExeVir Bio（ベルギー）、大正製薬ホールディングス株式会社（日本）、DiosCURE Therapeutics SE（ドイツ）である。

ページTOPに戻る

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.4 FORECASTING TECHNIQUES

3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.5.1 BOTTOM-UP APPROACH

3.5.2 TOP-DOWN APPROACH

3.6 DATA TRIANGULATION

3.7 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES

4.2.2 RISING DEMAND FOR PRECISION MEDICINE

4.2.3 INCREASING INVESTMENT IN NANOBODY RESEARCH AND DEVELOPMENT

4.3 RESTRAINTS

4.3.1 MANUFACTURING CHALLENGES AND HIGH PRODUCTION COSTS

4.4 OPPORTUNITY

4.4.1 GROWING DEVELOPMENT OF NEW APPLICATIONS OF NANOBODIES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL NANOBODY MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON CLINICAL TRIALS

5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL NANOBODY MARKET, BY TYPE

6.1 OVERVIEW

6.2 MONO-SPECIFIC

6.3 MULTI-SPECIFIC

7 GLOBAL NANOBODY MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 THERAPEUTIC

7.2.1 CANCER

7.2.2 NEURODEGENERATIVE DISEASES

7.2.3 INFECTIOUS DISEASES

7.2.4 OTHERS

7.3 DIAGNOSTIC

7.3.1 DETECTION OF PROTEINS AND MICROORGANISMS

7.3.2 DETECTION OF SMALL MOLECULES

7.3.3 IMAGING

7.4 RESEARCH

8 GLOBAL NANOBODY MARKET, BY END USER

8.1 OVERVIEW

8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

8.3 RESEARCH LABORATORIES

8.4 OTHERS

9 GLOBAL NANOBODY MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 UK

9.3.3 FRANCE

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 JAPAN

9.4.2 CHINA

9.4.3 INDIA

9.4.4 SOUTH KOREA

9.4.5 AUSTRALIA

9.4.6 REST OF ASIA PACIFIC

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 AFRICA

9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 COMPETITIVE BENCHMARKING

10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL NANOBODY MARKET

10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL NANOBODY MARKET

10.5 KEY DEVELOPMENT ANALYSIS

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL

10.6.2 MERGER/ ACQUISITION

10.6.3 PARTNERSHIP/ AGREEMENT/COLLABORATION

10.7 MAJOR PLAYERS SALES ANALYSIS

10.8 MAJOR PLAYERS R&D ANALYSIS

11 COMPANY PROFILES

11.1 SANOFI

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 PRODUCTS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 MERCK KGAA

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 PRODUCTS OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 BIOCYTOGEN

11.3.1 COMPANY OVERVIEWS

11.3.2 FINANCIAL OVERVIEW

11.3.3 PRODUCTS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 KEY STRATEGIES

11.4 PROTEINTECH GROUP, INC.

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 PRODUCTS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 KEY STRATEGIES

11.5 NOVARTIS AG

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 PRODUCTS OFFERED

11.5.4 KEY DEVELOPMENTSS

11.5.5 SWOT ANALYSIS

11.5.6 KEY STRATEGIES

11.6 GENSCRIPT

11.6.1 COMPANY OVERVIEWS

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 SENSEI BIOTHERAPEUTICS, INC

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 BERONI GROUP

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 PRODUCTS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 KEY STRATEGIES

11.9 EXEVIR BIO

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 PRODUCTS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 PRODUCTS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

11.11 DIOSCURE THERAPEUTICS SE

11.11.1 COMPANY OVERVIEW

11.11.2 FINANCIAL OVERVIEW

11.11.3 PRODUCTS OFFERED

11.11.4 KEY DEVELOPMENTS

11.11.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES

12.2 RELATED REPORTS

ページTOPに戻る

図表リスト

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 GLOBAL NANOBDOY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 3 GLOBAL NANOBDOY MARKET, FOR MONO-SPECIFIC, BY REGION, 2019–2030 (USD BILLION)

TABLE 4 GLOBAL NANOBDOY MARKET, FOR MULTI-SPECIFIC, BY REGION, 2019–2030 (USD BILLION)

TABLE 5 GLOBAL NANOBDOY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 6 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY REGION, 2019–2030 (USD BILLION)

TABLE 7 GLOBAL NANOBDOY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 8 GLOBAL NANOBDOY MARKET, FOR CANCER, BY REGION, 2019–2030 (USD BILLION)

TABLE 9 GLOBAL NANOBDOY MARKET, FOR NEURODEGENERATIVE DISEASES, BY REGION, 2019–2030 (USD BILLION)

TABLE 10 GLOBAL NANOBDOY MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019–2030 (USD BILLION)

TABLE 11 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD BILLION)

TABLE 12 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY REGION, 2019–2030 (USD BILLION)

TABLE 13 GLOBAL NANOBDOY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 14 GLOBAL NANOBDOY MARKET, FOR DETECTION OF PROTEINS AND MICROORGANISMS, BY REGION, 2019–2030 (USD BILLION)

TABLE 15 GLOBAL NANOBDOY MARKET, FOR DETECTION OF SMALL MOLECULES, BY REGION, 2019–2030 (USD BILLION)

TABLE 16 GLOBAL NANOBDOY MARKET, FOR IMAGING, BY REGION, 2019–2030 (USD BILLION)

TABLE 17 GLOBAL NANOBDOY MARKET, FOR RESEARCH, BY REGION, 2019–2030 (USD BILLION)

TABLE 18 GLOBAL NANOBDOY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 19 GLOBAL NANOBDOY MARKET, FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2030 (USD BILLION)

TABLE 20 GLOBAL NANOBDOY MARKET, FOR RESEARCH LABORATORIES, BY REGION, 2019–2030 (USD BILLION)

TABLE 21 GLOBAL NANOBDOY MARKET, FOR OTHERS, BY REGION, 2019–2030 (USD BILLION)

TABLE 22 GLOBAL: NANOBODY MARKET, BY REGION, 2019–2030 (USD BILLION)

TABLE 23 NORTH AMERICA: NANOBODY MARKET, BY COUNTRY, 2019–2030 (USD BILLION)

TABLE 24 NORTH AMERICA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 25 NORTH AMERICA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 26 NORTH AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 27 NORTH AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 28 NORTH AMERICA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 29 US: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 30 US: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 31 US: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 32 US: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 33 US: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 34 CANADA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 35 CANADA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 36 CANADA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 37 CANADA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 38 CANADA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 39 EUROPE: NANOBODY MARKET, BY COUNTRY, 2019–2030 (USD BILLION)

TABLE 40 EUROPE: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 41 EUROPE: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 42 EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 43 EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 44 EUROPE: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 45 GERMANY: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 46 GERMANY: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 47 GERMANY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 48 GERMANY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 49 GERMANY: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 50 UK: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 51 UK: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 52 UK: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 53 UK: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 54 UK: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 55 FRANCE: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 56 FRANCE: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 57 FRANCE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 58 FRANCE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 59 FRANCE: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 60 ITALY: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 61 ITALY: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 62 ITALY: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 63 ITALY: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 64 ITALY: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 65 SPAIN: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 66 SPAIN: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 67 SPAIN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 68 SPAIN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 69 SPAIN: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 70 REST OF EUROPE: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 71 REST OF EUROPE: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 72 REST OF EUROPE: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 73 REST OF EUROPE: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 74 REST OF EUROPE: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 75 ASIA PACIFIC: NANOBODY MARKET, BY COUNTRY, 2019-2030 (USD BILLION)

TABLE 76 ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 77 ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 78 ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 79 ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 80 ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 81 JAPAN: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 82 JAPAN: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 83 JAPAN: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 84 JAPAN: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 85 JAPAN: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 86 CHINA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 87 CHINA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 88 CHINA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 89 CHINA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 90 CHINA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 91 INDIA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 92 INDIA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 93 INDIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 94 INDIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 95 INDIA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 96 SOUTH KOREA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 97 SOUTH KOREA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 98 SOUTH KOREA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 99 SOUTH KOREA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 100 SOUTH KOREA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 101 AUSTRALIA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 102 AUSTRALIA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 103 AUSTRALIA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 104 AUSTRALIA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 105 AUSTRALIA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 106 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 107 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 108 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 109 REST OF ASIA-PACIFIC: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 110 REST OF ASIA-PACIFIC: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 111 REST OF THE WORLD: NANOBODY MARKET, BY REGION, 2019-2030(USD BILLION)

TABLE 112 REST OF THE WORLD: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 113 REST OF THE WORLD: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 114 REST OF THE WORLD: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 115 REST OF THE WORLD: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 116 REST OF THE WORLD: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 117 MIDDLE EAST: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 118 MIDDLE EAST: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 119 MIDDLE EAST: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 120 MIDDLE EAST: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 121 MIDDLE EAST: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 122 AFRICA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 123 AFRICA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 124 AFRICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 125 AFRICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 126 AFRICA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 127 LATIN AMERICA: NANOBODY MARKET, BY TYPE, 2019–2030 (USD BILLION)

TABLE 128 LATIN AMERICA: NANOBODY MARKET, BY APPLICATION, 2019–2030 (USD BILLION)

TABLE 129 LATIN AMERICA: NANOBODY MARKET, FOR THERAPEUTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 130 LATIN AMERICA: NANOBODY MARKET, FOR DIAGNOSTIC, BY TYPE, 2019–2030 (USD BILLION)

TABLE 131 LATIN AMERICA: NANOBODY MARKET, BY END USER, 2019–2030 (USD BILLION)

TABLE 132 MAJOR PLAYERS IN THE GLOBAL NANOBODY MARKET

TABLE 133 MOST ACTIVE PLAYER IN THE GLOBAL NANOBODY MARKET

TABLE 134 PRODUCT LAUNCH/PRODUCT APPROVAL

TABLE 135 MERGER/ ACQUISITION

TABLE 136 PARTNERSHIP/ AGREEMENT/COLLABORATION

TABLE 137 SANOFI: PRODUCTS OFFERED

TABLE 138 SANOFI: KEY DEVELOPMENTS

TABLE 139 MERCK KGAA: PRODUCTS OFFERED

TABLE 140 MERCK KGAA: KEY DEVELOPMENTS

TABLE 141 BIOCYTOGEN: PRODUCTS OFFERED

TABLE 142 BIOCYTOGEN: KEY DEVELOPMENTS

TABLE 143 PROTEINTECH GROUP, INC.: PRODUCTS OFFERED

TABLE 144 NOVARTIS AG: PRODUCTS OFFERED

TABLE 145 GENSCRIPT: PRODUCTS OFFERED

TABLE 146 SENSEI BIOTHERAPEUTICS: PRODUCTS OFFERED

TABLE 147 SENSEI BIOTHERAPEUTICS: KEY DEVELOPMENTS

TABLE 148 BERONI GROUP: PRODUCTS OFFERED

TABLE 149 BERONI GROUP: KEY DEVELOPMENTS

TABLE 150 EXEVIR BIO BV.: PRODUCTS OFFERED

TABLE 151 TAISHO PHARMACEUTICAL HOLDINGS CO., LTD: PRODUCTS OFFERED

TABLE 152 DIOSCURE THERAPEUTICS SE: PRODUCTS OFFERED

ページTOPに戻る

Table of Contents
List of Tables/Graphs

Summary

Nanobody Market Research Report Forecast till 2030

Market Overview
Nanobody Market is estimated to register a healthy CAGR of 17.88% for the projected period. The rising predominance of persistent sicknesses, rising interest for accuracy medication, and expanding interest in nanobody innovative work are driving market development.
Nanobodies are little counter acting agent parts that enjoy a few upper hands over conventional antibodies, like more prominent strength, better tissue infiltration, and decreased immunogenicity. The rising commonness of immune system illnesses and other ongoing issues requests the revelation of fresher and more viable nanobody-based drugs for their treatment. For example, in February 2019, the US Food and Medication Organization (FDA) endorsed Cablivi (caplacizumab-yhdp), the principal nanobody-based medication of Sanofi S.A. (France), for grown-ups with obtained thrombotic thrombocytopenic purpura (aTTP).
As per the World Health Organization (WHO), ongoing infections like malignant growth, cardiovascular illness, and diabetes are answerable for 74% of all passings internationally. The rate and predominance of these sicknesses are supposed to keep on rising, driven by variables like maturing populaces, evolving ways of life, and expanding urbanization. Consequently, the rising pervasiveness of ongoing illnesses, joined with the exceptional benefits of nanobodies drives the market development.

Market Segmentation
The Nanobody Market segmentation, based on type, includes mono-specific and multi-specific.
The Nanobody Market segmentation is based on application that include therapeutic, diagnostic, and research. The therapeutic segment is further segmented into cancer, neurodegenerative diseases, infectious diseases, and others.
Based on end user the market is segmented into research laboratories, pharmaceutical & biotechnology companies, and others.
Regional Analysis
The North America nanobody market accounted for the biggest market share in 2022. The regional market growth is attributed to the great mindfulness related with nanobodies innovation in drug revelation and improvement to decrease the expense of creation. Organizations like Proteintech Gathering, Inc. (US), and Genscript Biotech Organization (US) are effectively chipping away at further developing nanobodies and satisfying the requests of clients. The Genscript Biotech Partnership (US) offers exhaustive exploration and helpful nanobodies application administrations, and in a few examination studies, the organization has given rewarding learning experiences.
Europe nanobody market represents the second-largest market owing to the presence of dynamic market players, developing nanobodies new companies, and expanding predominance of illnesses, for example, irresistible, neurological, and disease. further, Germany nanobody market was ascribed to hold the biggest market share, and the France nanobody market is supposed to quickest developing market in the region.
The Asia-Pacific nanobody market is supposed to develop a fastest growth owing to the developing geriatric populace, expanding predominance of malignant growth and irresistible illnesses, and further developing examination abilities in the Asia-Pacific region. Additionally, China nanobody market is supposed to hold the biggest market offer, and India nanobody market is normal quickest developing market in the Asia-Pacific region.
Major Players
The prominent companies in the global Nanobody Market are Sanofi (France), Merck KGaA (Germany), BIOCYTOGEN (US), Proteintech Group, Inc (US), Novartis AG (Switzerland), GenScript (US), Sensei Biotherapeutics, Inc (US), Beroni Group (Australia), ExeVir Bio (Belgium), Taisho Pharmaceutical Holdings Co., Ltd (Japan), and DiosCURE Therapeutics SE (Germany).

ページTOPに戻る

List of Tables/Graphs

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Market Research Future 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Market Research Future社はどのような調査会社ですか?

マーケットリサーチフューチャー（Market Research Future）は世界市場を幅広く調査し、主要分野、地域、国レベルの調査レポートを出版しています。下記分野については、分野毎に専... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ナノボディ市場調査レポート：2030年までの予測

サマリー

目次

図表リスト

Summary

Table of Contents

List of Tables/Graphs

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Market Research Future 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Market Research Future社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?